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. Approved and banned top selling metformin FDCs in India. Table S1 . Approved and banned top selling metformin FDCs in India Fifty-two metformin FDCs have been approved by CDSCO over 20 years from February 1996 through to September 2016. 1 Of these 52, 12 were approvals for the 5 top sellers and of the different dosages for the 5 top-sellers, 10 were banned in March 2016 by the government. Glimepiride (1mg/2mg) + Pioglitazone (15mg) + Metformin (500mg E.R) uncoated Tablet, as 3rd line treatment of type-II diabetes mellitus when diet, exercise and the single agents and second line therapy with two drugs do nto result in adequate glycemic control; 16 such as study duration, number of patients, study arms, primary outcomes, sponsorship, and study country, were then extracted into an Excel file for further analysis. 3 Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews (2nd Edition). York, UK, Centre for Reviews and Dissemination, University of York, 2001. 4. diabetes with a study duration of 3-6 months [12] [13] [14] .
Evaluation of the 17 unpublished clinical trials against WHO FDC criteria (Table S7)
No trial results were posted on any of the clinical trial databases. Eight trials compared the FDC to SDF monotherapy; none investigated concomitant SDF treatments (Table S7) [15, 16] . The former compared the FDC to monotherapy (metformin or glibenclamide) and the latter FDC after concomitant treatment with a sulfonylurea plus metformin.
Involvement of multinational corporations (MNCs) and country of study
Of the 17 unpublished trials, only the Pakistan study was not conducted by a pharmaceutical company [10] . Sanofi-Aventis conducted five unpublished trials on the glimepiride FDC[1,2,6,9,11]. Abbott Healthcare conducted three of the unpublished trials in India [12] [13] [14] investigating the triple combination FDC.
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